Abstract
Aims: To evaluate the efficacy and safety of a commercially available phosphate-containing solution for continuous renal replacement therapy (CRRT) in preventing CRRT-related hypophosphatemia. Methods: In heart surgery patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) with regional citrate anticoagulation (RCA), we combined an 18 mmol/l citrate solution with a phosphate-containing (1.2 mmol/l) dialysate/replacement fluid evaluating the incidence of hypophosphatemia and the need for parenteral phosphorus supplementation. Results: In 75 patients on RCA-CVVHDF, the mean filter life was 53.9 ± 33.6 h. Regardless of baseline levels, phosphoremia was progressively corrected and maintained in a narrow normality range throughout RCA-CRRT days (after 72 h: 1.14 ± 0.25 mmol/l). Considering the whole CRRT period, 45 out of 975 (4.6%) serum phosphorus determinations met the criteria for mild (<0.81 mmol/l) or moderate (<0.61 mmol/l) hypophosphatemia; severe hypophosphatemia (<0.32 mmol/l) never occurred. After 72 h 88% of the patients were normophosphatemic, 9% hyperphosphatemic and 3% hypophosphatemic. Conclusions: RCA-CVVHDF with a phosphate-containing solution enabled the maintenance of phosphorus levels within normophosphatemic range in most of the patients, minimizing the occurrence of CRRT-related hypophosphatemia.
References
1.
Suzuki S, Egi M, Schneider AG, Bellomo R, Hart GK, Hegarty C: Hypophosphatemia in critically ill patients. J Crit Care 2013;28:536.e9-e19.
2.
Ronco C, Ricci Z, De Backer D, et al: Renal replacement therapy in acute kidney injury: controversy and consensus. Crit Care 2015;19:146.
3.
Troyanov S, Geadah D, Ghannoum M, Cardinal J, Leblanc M: Phosphate addition to hemodiafiltration solutions during continuous renal replacement therapy. Intensive Care Med 2004;30:1662-1665.
4.
Palevsky PM, Zhang JH, O'Connor TZ, et al: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7-20.
5.
Bellomo R, Cass A, Cole L, et al: Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009;361:1627-1638.
6.
Santiago MJ, López-Herce J, Urbano J, Bellón JM, del Castillo J, Carrillo A: Hypophosphatemia and phosphate supplementation during continuous renal replacement therapy in children. Kidney Int 2009;75:312-316.
7.
Demirjian S, Teo BW, Guzman JA, et al: Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. Nephrol Dial Transplant 2011;26:3508-3514.
8.
Broman M, Carlsson O, Friberg H, Wieslander A, Godaly G: Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy. Acta Anaesthesiol Scand 2011;55:39-45.
9.
Yang Y, Zhang P, Cui Y, et al: Hypophosphatemia during continuous veno-venous hemofiltration is associated with mortality in critically ill patients with acute kidney injury. Crit Care 2013;17:R205.
10.
Bugg NC, Jones JA: Hypophosphataemia. Pathophysiology, effects and management on the intensive care unit. Anaesthesia 1998;53:895-902.
11.
Morabito S, Pistolesi V, Tritapepe L, et al: Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care 2012;16:R111.
12.
Hetzel GR, Taskaya G, Sucker C, Hennersdorf M, Grabensee B, Schmitz M: Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2006;48:806-811.
13.
Fiaccadori E, Maggiore U, Cabassi A, Morabito S, Castellano G, Regolisti G: Nutritional evaluation and management of AKI patients. J Ren Nutr 2013;23:255-258.
14.
Sharma S, Brugnara C, Betensky RA, Waikar SS: Reductions in red blood cell 2,3-diphosphoglycerate concentration during continuous renal replacment therapy. Clin J Am Soc Nephrol 2015;10:74-9.
15.
Godaly G, Carlsson O, Broman M: Phoxilium(®) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy. Clin Kidney J 2016;9:205-210.
16.
Chua HR, Baldwin I, Ho L, Collins A, Allsep H, Bellomo R: Biochemical effects of phosphate-containing replacement fluid for continuous venovenous hemofiltration. Blood Purif 2012;34:306-312.
17.
Morabito S, Pistolesi V, Tritapepe L, et al: Regional citrate anticoagulation in CVVH: a new protocol combining citrate solution with a phosphate-containing replacement fluid. Hemodial Int 2013;17:313-320.
18.
Morabito S, Pistolesi V, Tritapepe L, et al: Continuous veno-venous hemofiltration using a phosphate-containing replacement fluid in the setting of regional citrate anticoagulation. Int J Artif Organs 2013;36:845-852.
19.
Morabito S, Pistolesi V, Tritapepe L, et al: Continuous venovenous hemodiafiltration with a low citrate dose regional anticoagulation protocol and a phosphate-containing solution: effects on acid-base status and phosphate supplementation needs. BMC Nephrol 2013;14:232.
20.
Geerse DA, Bindels AJ, Kuiper MA, Roos AN, Spronk PE, Schultz MJ: Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care 2010;14:R147.
21.
Kidney Disease Outcomes Quality Initiative: KDIGO clinical practice guidelines for acute kidney injury. Kidney Int Suppl 2012;2:124-138.
22.
James M, Bouchard J, Ho J, et al: Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 2013;61:673-685.
23.
Fiaccadori E, Pistolesi V, Mariano F, et al: Regional citrate anticoagulation for renal replacement therapies in patients with acute kidney injury: a position statement of the Work Group ‘Renal Replacement Therapies in Critically Ill Patients' of the Italian Society of Nephrology. J Nephrol 2015;28:151-164.
24.
Vinsonneau C, Allain-Launay E, Blayau C, et al: Renal replacement therapy in adult and pediatric intensive care: recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD). Ann Intensive Care 2015;5:58.
25.
Pistolesi V, Di Napoli A, Fiaccadori E, et al: Severe acute kidney injury following cardiac surgery: short-term outcomes in patients undergoing continuous renal replacement therapy (CRRT). J Nephrol 2016;29:229-239.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
